A-to-I RNA editing: The "ADAR" side of human cancer

Seminars in Cell and Developmental Biology

Volumn 23, Issue 3, 2012, Pages 244-250

  Galeano, Federica ^a   Tomaselli, Sara ^a   Locatelli, Franco ^a,b   Gallo, Angela ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

A to I RNA editing; ADAR enzymes; Human cancers

Indexed keywords

ADENOSINE DEAMINASE;

CANCER GENETICS; CARCINOGENESIS; ENZYME ANALYSIS; GENE MUTATION; HUMAN; NEOPLASM; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; REVIEW; RNA EDITING;

EID: 84860356214     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2011.09.003     Document Type: Review

References (66)

1. Keegan L.P., Gallo A., O'Connell M.A. The many roles of an RNA editor. Nat Rev Genet 2001, 2:869-878.
2. Gallo A., Locatelli F. ADARs: allies or enemies? The importance of A-to-I RNA editing in human disease: from cancer to HIV-1. Biol Rev Camb Philos Soc 2011.
3. Valente L., Nishikura K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog Nucleic Acid Res Mol Biol 2005, 79:299-338.
4. Nishikura K. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol 2006, 7:919-931.
5. Hartner J.C., Schmittwolf C., Kispert A., Muller A.M., Higuchi M., Seeburg P.H. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem 2004, 279:4894-4902.
6. Wang Q., Miyakoda M., Yang W., Khillan J., Stachura D.L., Weiss M.J., et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004, 279:4952-4961.
7. Higuchi M., Maas S., Single F.N., Hartner J., Rozov A., Burnashev N., et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 2000, 406:78-81.
8. Paul M.S., Bass B.L. Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. EMBO J 1998, 17:1120-1127.
9. Maas S., Rich A. Changing genetic information through RNA editing. Bioessays 2000, 22:790-802.
10. Athanasiadis A., Rich A., Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol 2004, 2:2144-2158.
11. Blow M., Futreal P.A., Wooster R., Stratton M.R. A survey of RNA editing in human brain. Genome Res 2004, 14:2379-2387.
12. Levanon E.Y., Eisenberg E., Yelin R., Nemzer S., Hallegger M., Shemesh R., et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol 2004, 22:1001-1005.
13. Knight S.W., Bass B.L. The role of RNA editing by ADARs in RNAi. Mol Cell 2002, 10:809-817.
14. Wang Q., Zhang Z., Blackwell K., Carmichael G.G. Vigilins bind to promiscuously A-to-I-edited RNAs and are involved in the formation of heterochromatin. Curr Biol 2005, 15:384-391.
15. Zhang Z., Carmichael G.G. The fate of dsRNA in the nucleus: a p54(nrb)-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell 2001, 106:465-475.
16. Schulte J.H., Marschall T., Martin M., Rosenstiel P., Mestdagh P., Schlierf S., et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010, 38:5919-5928.
17. Mizuguchi Y., Mishima T., Yokomuro S., Arima Y., Kawahigashi Y., Shigehara K., et al. Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PloS One 2011, 6:e15304.
18. He T., Wang Q., Feng G., Hu Y., Wang L., Wang Y. Computational detection and functional analysis of human tissue-specific A-to-I RNA editing. PloS One 2011, 6:e18129.
19. Hitchins M.P. Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility. Adv Genet 2010, 70:201-243.
20. Lechner M., Boshoff C., Beck S. Cancer epigenome. Adv Genet 2010, 70:247-276.
21. Stupp R., van den Bent M.J., Hegi M.E. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005, 5:198-206.
22. Gallo V., Ghiani C.A. Glutamate receptors in glia: new cells, new inputs and new functions. Trends Pharmacol Sci 2000, 21:252-258.
23. Bergles D.E., Roberts J.D., Somogyi P., Jahr C.E. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature 2000, 405:187-191.
24. Maas S., Patt S., Schrey M., Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 2001, 98:14687-14692.
25. Ishiuchi S., Tsuzuki K., Yoshida Y., Yamada N., Hagimura N., Okado H., et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 2002, 8:971-978.
26. 2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 2007, 27:7987-8001.
27. Paupard M.C., O'Connell M.A., Gerber A.P., Zukin R.S. Patterns of developmental expression of the RNA editing enzyme rADAR2. Neuroscience 2000, 95:869-879.
28. Cenci C., Barzotti R., Galeano F., Corbelli S., Rota R., Massimi L., et al. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem 2008, 283:7251-7260.
29. Paz N., Levanon E.Y., Amariglio N., Heimberger A.B., Ram Z., Constantini S., et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 2007, 17:1586-1595.
30. Ghosh S., Tewari R., Dixit D., Sen E. TNFalpha induced oxidative stress dependent Akt signaling affects actin cytoskeletal organization in glioma cells. Neurochem Int 2010, 56:194-201.
31. Stapleton M., Carlson J.W., Celniker S.E. RNA editing in Drosophila melanogaster: new targets and functional consequences. RNA 2006, 12:1922-1932.
32. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
33. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
34. Roylance R., Spurr N., Sheer D. The genetic analysis of prostate carcinoma. Semin Cancer Biol 1997, 8:37-44.
35. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002, 62:4499-4506.
36. Rhodes D.R., Barrette T.R., Rubin M.A., Ghosh D., Chinnaiyan A.M. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002, 62:4427-4433.
37. Rajan P., Elliott D.J., Robson C.N., Leung H.Y. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009, 6:454-460.
38. Martinez H.D., Jasavala R.J., Hinkson I., Fitzgerald L.D., Trimmer J.S., Kung H.J., et al. RNA editing of androgen receptor gene transcripts in prostate cancer cells. J Biol Chem 2008, 283:29938-29949.
39. Sun D., Lee Y.S., Malhotra A., Kim H.K., Matecic M., Evans C., et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011, 71:1313-1324.
40. Blow M.J., Grocock R.J., van Dongen S., Enright A.J., Dicks E., Futreal P.A., et al. RNA editing of human microRNAs. Genome Biol 2006, 7:R27.
41. Kawahara Y., Megraw M., Kreider E., Iizasa H., Valente L., Hatzigeorgiou A.G., et al. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res 2008, 36:5270-5280.
42. van der Groep P., van der Wall E., van Diest P.J. Pathology of hereditary breast cancer. Cell Oncol (Dordrecht) 2011, 34:71-88.
43. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
44. Monni O., Barlund M., Mousses S., Kononen J., Sauter G., Heiskanen M., et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 2001, 98:5711-5716.
45. Knowles M.A. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008, 13:287-297.
46. Zilberman D.E., Safran M., Paz N., Amariglio N., Simon A., Fridman E., et al. Does RNA editing play a role in the development of urinary bladder cancer?. Urol Oncol 2009.
47. Gromova I., Gromov P., Celis J.E. bc10: a novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer. Int J Cancer 2002, 98:539-546.
48. Yao J., Duan L., Fan M., Yuan J., Wu X. Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma: BLCAP overexpression induces S phase arrest and apoptosis. Mol Cell Biochem 2007, 297:81-92.
49. Galeano F., Leroy A., Rossetti C., Gromova I., Gautier P., Keegan L.P., et al. Human BLCAP transcript: new editing events in normal and cancerous tissues. Int J Cancer 2010, 127:127-137.
50. Talbot S.J., Crawford D.H. Viruses and tumours-an update. Eur J Cancer 2004, 40:1998-2005.
51. Cathomas G. Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 2003, 10:72-77.
52. Sadler R., Wu L., Forghani B., Renne R., Zhong W., Herndier B., et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol 1999, 73:5722-5730.
53. Muralidhar S., Veytsmann G., Chandran B., Ablashi D., Doniger J., Rosenthal L.J. Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene, kaposin (ORF K12). J Clin Virol 2000, 16:203-213.
54. Gandy S.Z., Linnstaedt S.D., Muralidhar S., Cashman K.A., Rosenthal L.J., Casey J.L. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J Virol 2007, 81:13544-13551.
55. Uribesalgo I., Di Croce L. Dynamics of epigenetic modifications in leukemia. Brief Funct Genomics 2011, 10:18-29.
56. Wang L., Huang G., Zhao X., Hatlen M.A., Vu L., Liu F., et al. Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cell Mol Dis 2009, 43:30-34.
57. Beghini A., Ripamonti C.B., Peterlongo P., Roversi G., Cairoli R., Morra E., et al. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum Mol Genet 2000, 9:2297-2304.
58. Dong Q., Siminovitch K.A., Fialkow L., Fukushima T., Downey G.P. Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. J Immunol 1999, 162:3220-3230.
59. Gauffin F., Diffner E., Gustafsson B., Nordgren A., Wingren A.G., Sander B., et al. Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia. Pediatr Hemat Oncol 2009, 26:48-56.
60. Hartner J.C., Walkley C.R., Lu J., Orkin S.H. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 2009, 10:109-115.
61. XuFeng R., Boyer M.J., Shen H., Li Y., Yu H., Gao Y., et al. ADAR1 is required for hematopoietic progenitor cell survival via RNA editing. Proc Natl Acad Sci USA 2009, 106:17763-17768.
62. Castor A., Nilsson L., Astrand-Grundstrom I., Buitenhuis M., Ramirez C., Anderson K., et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005, 11:630-637.
63. Ma C.H., Chong J.H., Guo Y., Zeng H.M., Liu S.Y., Xu L.L., et al. Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. Biochem Biophys Res Commun 2011, 406:245-251.
64. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
65. Yang W., Chendrimada T.P., Wang Q., Higuchi M., Seeburg P.H., Shiekhattar R., et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 2006, 13:13-21.
66. Wang F., Wang X.S., Yang G.H., Zhai P.F., Xiao Z., Xia L.Y., et al. miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 2011.